• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Verily, Sanofi and other industry players team up with NIH to advance Parkinson’s therapies

January 30, 2018 By Sarah Faulkner

National Institutes of Health logoThe National Institutes of Health is joining forces with the tech and pharmaceutical industries to speed the development of new drugs for Parkinson’s disease and identify biomarkers for the debilitating condition.

Companies participating in the public-private partnership include Celgene (NSDQ:CELG), GlaxoSmithKline (NYSE:GSK), The Michael J. Fox Foundation for Parkinson’s Research, Pfizer (NYSE:PFE), Sanofi (NYSE:SNY) and Verily. Combined the groups plan to commit $12 million to effort, which the NIH is slated to match.

“Advancing treatments for Parkinson’s disease is hampered by insufficient understanding of biological networks; drugs aimed at seemingly promising therapeutic targets fail in clinical trials,” NIH Director Dr. Francis Collins said in prepared remarks. “By combining our expertise and resources, [Accelerating Medicines Partnership] PD partners hope to increase our collective odds of success in accelerating the development of effective treatments for a million Americans who suffer from this debilitating disease.”

“There is a wealth of biosamples and data already collected by NIH and MJFF from people with Parkinson’s disease,” Dr. Walter Koroshetz, director of the NIH’s National Institute of Neurological Disorders and Stroke, added. “Sharing resources from public-private partnerships to generate and analyze ‘big data’ made available through AMP may be our greatest opportunity for accelerating the pace of discovery for translation into more effective treatments for PD.”

As part of the collaboration, Verily plans to develop a shared Knowledge Portal that will house the data from cerebrospinal fluid, RNA, plasma and DNA samples collected from more than 3,000 people with Parkinson’s disease, alongside samples from 1,700 healthy participants.

The group will them comb through the datasets to find biomarkers that could help predict disease progression and prognosis. Results from these analyses will be shared on the Knowledge Portal across the companies in the partnership and to the broader research community, according to the NIH.

“The AMP PD Knowledge Portal will provide data storage, pipelines and visualization tools that could enable unique opportunities for data science solutions for human disease modeling and for the identification of the underlying biology related to PD pathogenesis,” Margaret Sutherland, NINDS program director and co-chair of the AMP PD steering committee, said.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Clinical Trials, Featured, Neurological, Pharmaceuticals, Wall Street Beat Tagged With: Celgene, GlaxoSmithKline plc, michaeljfoxfoundation, National Institutes of Health, Pfizer Inc., Sanofi-Aventis, Verily

IN CASE YOU MISSED IT

  • FDA approves first targeted infusion therapy for HER2-low breast cancer
  • Abbott, WeightWatchers partner on diabetes care
  • Insulet up on Q2 sales beat, raised full-year guidance
  • Aptar acquires Orbital dry powder inhaler license
  • Tandem sinks on Q2 misses, slashed sales guidance

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS